Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Greta Thunberg urges voters to elect Joe Biden

Greta Thunberg on Saturday asked US voters to vote for Joe Biden, saying the outcome of the US presidential election was crucial for fighting climate change

Swedish environmental campaigner Greta Thunberg on Saturday asked US voters to vote for Joe Biden, saying the outcome of the US presidential election was crucial for fighting climate change. Thunberg has had many a run-ins with the US president Donald Trump, who has on numerous occasions played down climate change. Biden on the other hand has reached out to Thunberg and hailed her commitment to the fight against climate change. Last month, the respected magazine Scientific American also urged readers to vote for Biden on November 3, the first time in almost 200 years that it has taken a political stance.

British activist launches 'world's most northerly climate strike'

18-year-old British activist and Ornithologist&nbsp;Mya-Rose craig&nbsp;has launched the 'world's most northerly climate strike' on the Arctic Ocean.

Mya-Rose craig, an 18-year-old British activist and Ornithologist has taken part in a unique climate strike. She stood on a melting ice floe in the Arctic Ocean, 82 degrees north and held a placard that read 'Youth Strike for Climate', an act that is being dubbed as the 'world's most northerly climate strike'. Students, globally, have been striking on Fridays for two years now, as a part of a movement by Swedish climate activist Greta Thunberg. The Fridays For Future movement has thousands of protests planned across the globe this week.

Mya-Rose craig, an 18-year-old British activist and Ornithologist has taken part in a unique climate strike.
She stood on a melting ice floe in the Arctic Ocean, 82 degrees north and held a placard that read 'Youth Strike for Climate', an act that is being dubbed as the 'world's most northerly climate strike'.
Students, globally, have been striking on Fridays for two years now, as a part of a movement by Swedish climate activist Greta Thunberg. The Fridays For Future movement has thousands of protests planned across the globe this week.
A U.S. report stated that ice in the Arctic Ocean melted to its second lowest level on record this summer, fuelled by global warming. Known as Birdgirl online, her protest serves as a wake up call and seeks urgent action to protect what's left in the future.

Serum Institute gets nod to resume Covid vaccine trials

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate

Drugs Controller General of India on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate. The DCGI, Dr V G Somani, has however, put certain conditions like taking extra care during screening, providing additional information in informed consent to be followed during the trials. The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of "an unexplained illness" in a volunteer.

New Delhi, PTI: Drugs Controller General of India (DCGI) Dr V G Somani on Tuesday gave permission to Serum Institute of India to resume clinical trial of the Oxford Covid-19 vaccine candidate in the country while revoking its earlier order of suspending any new recruitment for phase two and three trial.
The DCGI, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study which have to be "scrupulously" followed by Serum Institute of India (SII).
SII has also been asked to submit to the DCGI's office details of medication used in accordance with the protocol for management of adverse events.
The DCGI had on September 11 directed Serum Institute of India to suspend any new recruitment in the phase two and three clinical trial of the Oxford Covid-19 vaccine candidate till further orders in the backdrop of pharma giant AstraZeneca pausing the clinical trials in other countries because of ''an unexplained illness'' in a participant in the study.
On Saturday, British-Swedish biopharmaceutical giant AstraZeneca and the University of Oxford said clinical trials for their coronavirus vaccine have resumed in the UK after the Medicines Health Regulatory Authority's (MHRA) confirmed that the trials were safe.
SII, which has partnered with AstraZeneca for manufacturing the vaccine candidate for Covid-19, on Tuesday submitted the recommendations of the Data and Safety Monitoring Board (DSMB), UK and DSMB, India, and requested for permission to restart enrolment in the clinical trial.
According to Tuesday's order issued by DCGI, the DSMB, UK, recommended that the investigators recommence all immunization in their clinical trials subject to certain conditions.
DSMB, India, also has recommended to continue the study and enroll the remaining participants in the clinical trial as per protocol subject to certain conditions.
According to the order, SII has submitted revised participant information sheet, revised informed consent form and additional safety monitoring plan for the evolved participants.

Serum India told to halt recruitment for vaccine trials

India's drug regulator has directed Serum Institute of India to suspend recruitment of new volunteers for phase 2 and 3 clinical trials of the Oxford Covid-19 vaccine candidate

India's drug regulator has directed Serum Institute of India to suspend recruitment of new volunteers for phase 2 and 3 clinical trials of the Oxford Covid-19 vaccine candidate. The directive came in the backdrop of pharma giant AstraZeneca pausing the trials in other countries. The DCGI on Friday also directed Serum Institute to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report. The drugmaker&nbsp;had on Thursday hit a pause after AstraZeneca put the trials on hold following an unexplained illness in a volunteer in the UK.

New Delhi, PTI: Drugs Controller General of India (DCGI) has directed Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the Oxford Covid-19 vaccine candidate in the backdrop of pharma giant AstraZeneca pausing the trials in other countries.
In an order, a copy of which has been accessed by PTI, DCGI Dr V G Somani on Friday also directed Serum Institute of India (SII) to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.
Somani also asked the firm to submit clearance from Data and Safety Monitoring Board (DSMB) in the UK as well as in India to obtain clearance from his office (DCGI) prior to resumption of future recruitment in the trial. The central drug regulator DCGI had issued a show-cause notice to SII on September 9 for not informing it about AstraZeneca pausing clinical trials of the vaccine candidate in other countries and also for not submitting casualty analysis of the "reported serious adverse events".
Following which the Pune-based firm, which has partnered with the British-Swedish biopharmaceutical giant AstraZeneca for manufacturing the Oxford vaccine candidate, on Thursday said it is pausing the clinical trials in India.
Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study. "We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials," SII said in a statement on Thursday. According to the DCGI's order issued on Friday, the SII in its reply stated that DSMB has noted no safety concerns from the Indian study (part 1-phase-2 study) with the first dose and seven days post vaccination safety data. In its reply, SII also stated that DSMB further recommended "to pause further enrolment into the study until ongoing investigations of SAE reported in the UK study is completed and the sponsor and the UK DSMB are satisfied that it doesn't pose any safety concerns".
"In the view of the above, I Dr V G Somani, Drugs Controller General of India, Central Licensing Authority, after careful examination of your reply and the recommendations of the DSMB in India, in exercise of the powers vested under Rule 30 of the New Drugs and Clinical Trials Rules, 2019, direct to you suspend any new recruitment in the phase 2 and 3 clinical trial till further orders," the order read.
"Increase the safety monitoring of the subjects already vaccinated with the vaccine under trial and submit the plan and report," the order further stated.

Zlatan Ibrahimovic extends his contract at AC Milan

Zlatan&nbsp;had&nbsp;arrived as a free agent in January 2020 from LA Galaxy and initially signed until the end of that season.

He may be turning 39 in October but&nbsp;Zlatan Ibrahimovic&nbsp;is certainly not done yet. The Swedish striker has signed a one-year contract extension with AC Milan after resuming pre-season training with his team-mates on Monday. Zlatan&nbsp;had&nbsp;arrived as a free agent in January 2020 from LA Galaxy and initially signed until the end of that season. The former Manchester United player scored 10 goals with five assists in 17 competitive games since moving back to Milan.&nbsp;

swedish

Categories